Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
This years’ #WCO-IOF-ESCEO Congress, from 20-22 August, will be virtual and UCB is thrilled to be working with @Dr_BoAbrahamsen at the congress. Listen to this short clip & find out more about #osteoporosis.
— UCB News (@ucb_news) 14.08.2020 -
We are delighted to be taking part at this year’s virtual #WCO-IOF-ESCEO congress, where we are pleased to be working with Prof Gaetano De Ferrari who along with his peers will be discussing the latest developments in osteoporosis and fragility fracture c
— UCB News (@ucb_news) 12.08.2020 -
We joined forces with several partners to boost the development of new therapies to combat #COVID19. Through our corporate venture fund UCB Ventures, we took part in the creation of ExeVir Bio, a company focused on harnessing the power of its llama based
— UCB News (@ucb_news) 10.08.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
